Edition:
United Kingdom

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

5,190.00ILa
3:09pm BST
Change (% chg)

-50.00 (-0.95%)
Prev Close
5,240.00
Open
5,200.00
Day's High
5,247.00
Day's Low
5,162.00
Volume
958,623
Avg. Vol
1,050,757
52-wk High
16,940.00
52-wk Low
5,162.00

Chart for

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 1.24
Market Cap(Mil.): ₪65,841.12
Shares Outstanding(Mil.): 1,014.36
Dividend: 30.51
Yield (%): 6.31

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

BRIEF-Teva announces submission of biologics license application for Fremanezumab to U.S. FDA

* Teva announces submission of biologics license application for Fremanezumab to the U.S. FDA

1:19pm BST

RULING BY FEDERAL JUDGE IN TEXAS IS VICTORY FOR GENERIC DRUGMAKERS MYLAN, TEVA

RULING BY FEDERAL JUDGE IN TEXAS IS VICTORY FOR GENERIC DRUGMAKERS MYLAN, TEVA

16 Oct 2017

BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva

* BioDelivery Sciences announces patent litigation settlement agreement with Teva

12 Oct 2017

Teva's Copaxone faces generic competition in Europe after U.S. hit

LONDON Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market.

05 Oct 2017

UPDATE 1-Teva's Copaxone faces generic competition in Europe after U.S. hit

LONDON, Oct 5 Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market.

05 Oct 2017

Teva's Copaxone faces more generic competition in Europe

LONDON, Oct 5 Teva's blockbuster multiple sclerosis treatment Copaxone faces more generic competition in Europe, just two days after regulators approved cut-price copies of the medicine in the United States.

05 Oct 2017

Mylan surges, Teva slumps after FDA approves Copaxone copy

Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.

04 Oct 2017

Mylan surges, Teva slumps after FDA approves Copaxone copy

Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.

04 Oct 2017

UPDATE 4-Mylan surges, Teva slumps after FDA approves Copaxone copy

Oct 4 Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.

04 Oct 2017

BRIEF-Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate

* Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate 40mg/ml and launch of generic Glatiramer Acetate 20mg/ml

04 Oct 2017

Earnings vs. Estimates